2-(4-Fluorophenyl)Thiazole-4-Carboxylic Acid Ethyl Ester, 95+%

Residual Solvent Class 2 Thresholds Shape Downstream Crystallization of the Fluorinated Thiazole Carboxylate

In routine GMP manufacturing of the advanced intermediate destined for a systemic triazole antifungal active pharmaceutical ingredient, the ethyl ester is hydrolysed under strictly controlled temperature to maintain stereochemical integrity of the downstream chiral carboxamide. The free acid form, obtained via LiOH‑mediated saponification in THF/H₂O (2:1 v/v) at 0–5 °C, must not exceed a hold time of 45 minutes after quench; otherwise decarboxylation of the 4‑carboxylic acid generates the 4‑H‑thiazole impurity at levels exceeding 0.15 area%, a threshold correlated with particle‑size‑driven filtration failures during final API crystallisation. The active ester species is pre‑formed using HOBt/EDC·HCl (1.05 eq.) in anhydrous DMF at -10 °C and immediately coupled with the chiral (R)‑amine intermediate at a molar ratio of 1.00–1.05 eq. relative to the amine. A slight stoichiometric excess beyond 1.07 eq. has been observed on production‑scale campaigns (glass‑lined reactors, 500–2000 L jacket‑controlled) to promote bis‑acylated impurity exceeding 0.3%, forcing a re‑crystallisation step that erodes overall yield by 12–15%. Regulatory compliance requires adherence to ICH Q7 (Active Pharmaceutical Ingredients GMP), ICH Q3C(R8) for residual Class 2 solvents (DMF ≤ 880 ppm, acetonitrile ≤ 410 ppm), and ICH Q3D(R2) elemental impurity limits—particularly palladium ≤ 10 µg/g and iron ≤ 100 µg/g when the route traces through a Suzuki coupling earlier in the sequence. The process is monitored by in‑line ReactIR tracking the anhydride carbonyl stretching band at ~1960 cm⁻¹; deviation of the normalised peak area by more than 8% triggers an automated hold to prevent uncontrolled exothermic release during the amidation phase. The terminal dosage form is a lyophilised powder for injection or an enteric‑coated tablet containing the fluorinated thiazole‑carboxamide antifungal substance, typically formulated at 50 mg or 200 mg freebase equivalent per unit.

When transitioning from greenhouse lead optimisation to pilot‑plant production of a thiazole‑carboxamide succinate dehydrogenase inhibitor (SDHI) fungicide, the ethyl ester intermediate requires rigorous acid‑number monitoring to prevent premature precipitation of the free carboxylic acid during the telescoped condensation‑cyclisation sequence. The scaffold is routinely deployed as a bioisostere of the pyrazol‑4‑carboxamide warhead to circumvent G143A and H272Y resistance mutations in Botrytis cinerea and Zymoseptoria tritici populations. The ethyl ester is introduced at a molar ratio of 1.02:1 relative to 2‑amino‑5‑ethylthiazole in the key amide‑bond‑forming step catalysed by CDI (1.10 eq.) in anhydrous acetonitrile at 25–30 °C. The narrow stoichiometric window prevents residual free amine from carrying forward to the final suspension concentrate, where trace amine can promote Ostwald ripening of the active ingredient particles and lead to caking during accelerated storage at 54 °C (OECD 506 stability protocol). After aqueous quench and filtration, the crude active compound is purified by slurry washing with isopropanol/water (1:3) to obtain an HPLC purity of ≥98.5%. Downstream formulation into a 250 g/L SC employs a GEA Niro Soavi high‑pressure homogeniser (two‑stage, 500/50 bar) with a target particle size D90 ≤ 3.0 µm; the ethoxylated tristyrylphenol phosphate surfactant load is held at 2.8–3.2% w/w to comply with aquatic ecotoxicity cut‑offs under EC Regulation 1107/2009 and EPA 40 CFR Part 158. Residue analytical methods must achieve a limit of quantification (LOQ) of 0.01 mg/kg in grape must and potato tuber for EU MRL compliance. Finished product classes are a 250 g/L SC for vineyard spray programmes and a 50% WDG for potato late blight control, with the active ingredient designated as a Group 7 SDHI by the Fungicide Resistance Action Committee. A batch‑record deviation that allowed residual ethyl ester contamination above 0.8 mol% in the carboxylic acid feed resulted in a cross‑ester impurity that co‑crystallised with the active, reducing the suspension’s zeta potential to −18 mV and causing rapid sedimentation in the spray tank—a failure mode captured in root‑cause analysis shared across multiple toll manufacturers.

Can a Single‑Thiazole Pharmacophore Deliver Broad‑Spectrum Ectoparasite Control Without Cross‑Resistance to Isoxazolines?

Lead optimisation programmes for companion‑animal ectoparasiticides have explored the 2‑(4‑fluorophenyl)thiazole‑4‑carbonyl motif as a novel binding determinant for invertebrate GABA‑gated chloride channels that remains efficacious against ticks carrying the A301S mutation known to compromise isoxazoline‑type compounds. The ethyl ester serves as the late‑stage building block in a one‑pot tandem amidation‑cyclisation sequence: after alkaline hydrolysis to the carboxylate with KOH (1.05 eq.) in EtOH/H₂O at reflux, the free acid is activated with thionyl chloride (1.20 eq.) in toluene containing catalytic DMF to generate the acyl chloride in situ. The subsequent coupling with a hydrazonomethyl‑substituted aryl aldehyde requires a stoichiometry of 1.2–1.3 eq. of the acyl chloride relative to the aldehyde component, compensating for side‑reaction with adventitious water that reduces the instantaneous concentration of the electrophile in the toluene‑potassium tert‑butoxide slurry. The entire sequence is executed in a single Hastelloy C22‑clad vessel under a nitrogen pad; oxygen ingress below 100 ppm is critical because the thiazole C‑2 position undergoes oxidative homocoupling when exposed to dissolved O₂ above 500 ppb, generating a bridged dimer that co‑elutes with the desired product during normal‑phase chromatography. Purification employs a Biotage Isolera™ system with a 300 g silica cartridge, gradient Hex/EtOAc 4:1 to 1:1, and the fraction containing the >99% pure intermediate is concentrated on a wiped‑film evaporator at 45 °C jacket temperature to avoid thermal degradation. Veterinary regulatory dossiers must satisfy VICH GL18 (Residue Chemistry), EMA/CVMP/VICH/751 on analytical validation, and US FDA CVM guidance #213 (Judicious Use). The final active is blended with a palatability enhancer (dried porcine liver powder) and a crospovidone disintegrant to produce a scored chewable tablet in 10 mg, 25 mg, or 50 mg strengths that delivers ≥ 95% flea knockdown at 24 hours for a full month. An incompatibility of note: residual methoxyethanol from the penultimate ether‑formation step, if above 50 ppm, produces a bitter off‑taste that reduces voluntary acceptance in Beagle panel tests below the 80% threshold required for a “palatable” label claim.

Metalation of the thiazole C–H bond adjacent to the 4‑carboxylate proceeds with exclusive ortho‑selectivity when the ethyl ester is treated with lithium tetramethylpiperidide (LiTMP) at −78 °C in anhydrous 2‑Me‑THF, a key activation step in synthesising heteroleptic iridium(III) emitters for red phosphorescent organic light‑emitting diodes. The ethyl ester group remains intact during the lithiation‑electrophilic quench sequence, preserving the carboxylate handle for subsequent cyclometalation with IrCl₃·3H₂O. The ligand precursor is reacted with the iridium source at a ratio of 2.5–3.0 molar equivalents in a degassed mixture of glycerol/ethylene glycol (3:1 v/v) at 200 °C for 24 hours under argon. Reducing the ratio below 2.2 eq. favours the formation of the homoleptic fac‑isomer and lowers the yield of the target heteroleptic complex to below 35%, a critical process‑intensification trade‑off documented in kilogram‑scale campaigns where the cost of the fluorinated thiazole precursor dominates the bill of materials. The crude complex is chromatographed on deactivated neutral alumina (grade III) with CH₂Cl₂/petroleum‑ether (1:1) and then gradient‑sublimed at 300 °C/10⁻⁶ Torr in a multi‑zone tube furnace to achieve a sublimation‑assisted purity of 99.98% (HPLC, 254 nm). The emission layer fabricated by co‑deposition with CBP host at a doping concentration of 6 wt% attains a peak external quantum efficiency exceeding 20% at a luminance of 1000 cd/m², with CIE coordinates (0.65, 0.34). Compliance with RoHS Directive 2011/65/EU mandates that any lead, mercury, or cadmium contamination introduced during the Grignard preparation of the fluorophenyl precursor must remain below the respective maximum concentration values (1000 ppm for lead) in the final sublimed batch. A REACH registration dossier is mandatory for quantities placed on the EU market exceeding 1 tonne per annum; the ethyl ester itself is classified as a non‑phase‑in substance requiring a full Annex VII–X data package. Sodium ion contamination, a common artefact when the ester is washed with brine before distillation, must be reduced to < 2 ppm by treatment with ethereal HCl, because residual sodium migrates under the electric field in the operational OLED stack and creates leakage‑current pathways that halve the half‑life of the device at 50 mA/cm² constant‑current stress.